UK regulator MHRA unveils multi-year plan to speed AI-driven drug oversight

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released a multi-year strategy aimed at keeping its regulatory framework patient-focused as artificial intelligence and personalized medicine become more prevalent.

The plan, which runs through 2030, sets out a series of commitments and actions the agency will take to stay abreast of rapid scientific and technological change, with the goal of delivering safe and effective treatments to patients more quickly.

In related regulatory commentary, stakeholders in the United States have urged the Food and Drug Administration to adopt flexible approaches for psychedelic-based therapies, emphasizing the need to avoid unnecessary barriers, ensure proper training, and allow labeling updates as new data emerge.